Age-related macular degeneration therapy: a review
Current opinion in ophthalmology, 2020•journals.lww.com
There are promising new strategies for AMD. Many of the potential new treatments are in or
have recently completed phase 2 or phase 3 clinical trials with promising results thus far,
including some that have received US Food and Drug Administration approval. Additional
therapeutic breakthroughs will likely continue to occur thanks to the number of clinical trials
that are nearing the finish line.
have recently completed phase 2 or phase 3 clinical trials with promising results thus far,
including some that have received US Food and Drug Administration approval. Additional
therapeutic breakthroughs will likely continue to occur thanks to the number of clinical trials
that are nearing the finish line.
Summary
There are promising new strategies for AMD. Many of the potential new treatments are in or have recently completed phase 2 or phase 3 clinical trials with promising results thus far, including some that have received US Food and Drug Administration approval. Additional therapeutic breakthroughs will likely continue to occur thanks to the number of clinical trials that are nearing the finish line.
Lippincott Williams & Wilkins